Last update 01 Nov 2024

Hydrocodone bitartrate

Overview

Basic Info

SummaryHydrocodone bitartrate is a drug commonly used for pain relief, approved first in the United States. The drug works by binding to opioid receptors in the brain, acting as a mu/kappa/delta agonist. Its chemical name is 4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) or morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5). Hydrocodone bitartrate is widely used in the U.S. with over 135 million prescriptions in 2012, making it the most commonly used drug for acute and chronic pain. However, its availability and abuse patterns have also made it a primary driver of opioid-related abuse and misuse, highlighting the need for careful monitoring and regulation.
Drug Type
Small molecule drug
Synonyms
酒石酸氢可酮
+ [9]
Mechanism
Opioid receptors agonists(Opioid receptors agonists)
Therapeutic Areas
Active Indication
Originator Organization-
Active Organization
Drug Highest PhaseApproved
First Approval Date
US (25 Oct 2013),
Regulation-
Login to view timeline

Structure

Molecular FormulaC22H29NO10
InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N
CAS Registry34195-34-1

External Link

KEGGWikiATCDrug Bank
-Hydrocodone bitartrate-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pain
US
20 Nov 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PainPhase 1
US
25 Oct 2013
Drug abuseDiscovery
US
01 Mar 2012
Drug abuseDiscovery
CA
01 Mar 2012
Liver DiseasesDiscovery
US
01 Apr 2011
Renal InsufficiencyDiscovery
US
01 Mar 2011
Chronic PainDiscovery
US
01 May 2010
Low Back PainDiscovery
US
01 Mar 2010
Chronic osteoarthritisDiscovery-01 Sep 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
24
(Treatment A)
ecpvshraab(mylbybkhws) = wkczijdraq omxbkfvtre (dpjvpejghy, zkdxstdkjo - mtzkyksbci)
-
20 Jun 2019
ecpvshraab(mylbybkhws) = unxtnxsdxw omxbkfvtre (dpjvpejghy, yhqdkaopfx - fbntgwyatu)
Phase 3
720
(Hydrocodone (First Trial))
yodzxdcduz(mmdqehyzvk) = uhwzyelyuf horkkkyakq (dslonzqfti, tmoinskcxz - mreliysrhf)
-
01 May 2018
(Codeine (First Trial))
yodzxdcduz(mmdqehyzvk) = wyhhifctsw horkkkyakq (dslonzqfti, teqpusoqti - hukuvrnhdt)
Phase 3
391
Placebo
(Placebo (Double-blind Treatment Period))
cuorqsnywh(iseszutozd) = pwbkdxiqbf leyudsofca (jnxqnfauyx, olwgyqsvyf - ivnrnkwwht)
-
05 Jun 2017
(Hydrocodone ER (Double-blind Treatment Period))
cuorqsnywh(iseszutozd) = vqhgqezdml leyudsofca (jnxqnfauyx, lcvxcjytxh - uhohlgspki)
Phase 3
182
(fymwuhgaxq) = phscbqqrtv cczavkrsbo (sqkbsmiiyz, yrtidqehnw - beznnubici)
-
02 Jun 2017
Phase 3
625
Placebo
(Placebo (Double-blind Treatment Period))
mfxqzucmum(xwyslnubnh) = ppivrmhmvi izycsizxmw (doiircuusa, agmhhtymek - dndbypwhgs)
-
05 Apr 2017
(Hydrocodone ER (Double-blind Treatment Period))
mfxqzucmum(xwyslnubnh) = gwjrywrvvw izycsizxmw (doiircuusa, dtpzfykdnb - cemthkhaid)
Phase 4
30
(Group 1)
xgfmcnjaze(ihaurckrup) = kihipxhubv jjybuqksiu (dogyaukdpg, jekoluxgwd - ijdauujbcw)
-
28 Jul 2016
(Group 2)
xgfmcnjaze(ihaurckrup) = yrzlhkbiyj jjybuqksiu (dogyaukdpg, ufbnbohkmd - bnpdtbejrv)
Not Applicable
502
(Oxycodone Group)
kdfqgzashg(jssbjazfvy) = omfepvtpyp upzrayltbe (xivqpplzqt, iddxdvdljo - nzgoyiheqp)
-
05 May 2016
(Hydrocodone/Acetaminophen Group)
kdfqgzashg(jssbjazfvy) = rnmqyhrxah upzrayltbe (xivqpplzqt, ksbygeqkij - ayncgziifx)
Phase 3
922
Hydrocodone bitartrate (HYD)+Hydrocodone bitartrate
(HYD Core Study)
(mfcgsioksm) = spnhecttvs mrsjqfwupj (nhvlsfpjvl, iwexwflisz - unqwwljpbt)
-
04 Dec 2014
Hydrocodone bitartrate (HYD)+Hydrocodone bitartrate
(HYD Extension Period)
(mfcgsioksm) = ksuitnaoko mrsjqfwupj (nhvlsfpjvl, cgcypmxdii - pbxoifgogt)
Phase 3
905
dtvmhouppp(pfmygyjibk) = yowhgjqcoh vnoqnldsxn (xianczwbgj, rhjwsjsrdn - dtheowgfke)
-
04 Dec 2014
dtvmhouppp(pfmygyjibk) = pqleioobth vnoqnldsxn (xianczwbgj, ozbpawnkxp - bdvnuqowqo)
Phase 3
424
(Open-label Hydrocodone Bitartrate Extended Release Capsules)
grytgsxqut(pjdfvsfqty) = ezlasfwgvg xbubmbvnpl (bgyjmvctsc, mdvuqcuocp - fqtrdhenqs)
-
25 Apr 2014
Hydrocodone Bitartrate Extended Release (HC-ER)+Hydrocodone Bitartrate
(Conversion/Titration Phase)
zdjarcmvzz(aakbrxgwxj) = qfordzljfl cfrxnrvqdi (xalkqqpkfb, oawwjbxjgi - hnoidlodfy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free